Sonia Graziano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sonia Graziano has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra L. Quittner
Joe DiMaggio Cystic Fibrosis, Pulmonary and Sleep Center Hollywood Florida USA
8 shared publications - Anna M. Georgiopoulos
Massachusetts General Hospital, Boston, MA, USA
5 shared publications Paola Tabarini
Psychology Unit, Child & Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
5 shared publicationsBeth Smith
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
4 shared publicationsFrancesca Boldrini
Psychology Unit, Child & Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
4 shared publications- Christina Jayne Bathgate
Department of Medicine National Jewish Health Denver Colorado USA
3 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2625
Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence
Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastrointestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Seven relevant studies were identified and qualitatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing confirmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated improvement in bowel dilatation and hyperchogenity. The infant was delivered at 36 + 2, passed meconium spontaneously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence the early trajectory of CF, potentially by preventing MI and potentially delaying the progression to pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.
- 30 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2625
Open AccessPrenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence
Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastrointestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Seven relevant studies were identified and qualitatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing confirmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated improvement in bowel dilatation and hyperchogenity. The infant was delivered at 36 + 2, passed meconium spontaneously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence the early trajectory of CF, potentially by preventing MI and potentially delaying the progression to pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.
- Open Access
- 25 February 2026
- Published by MDPI AG in Preprints.org
Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Review of the Emerging Evidence
Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastro-intestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in-utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Ten relevant studies were identified and quali-tatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing con-firmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated im-provement in bowel dilatation and hyperchogenity. The infant was delivered at 36 +2, passed meconium spontane-ously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence early trajectory of CF, potentially by preventing MI and preserve pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.
- 25 February 2026
- Published by MDPI AG in Preprints.org
Open AccessPrenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Review of the Emerging Evidence
Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastro-intestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in-utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Ten relevant studies were identified and quali-tatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing con-firmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated im-provement in bowel dilatation and hyperchogenity. The infant was delivered at 36 +2, passed meconium spontane-ously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence early trajectory of CF, potentially by preventing MI and preserve pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.
- 12 November 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (11) , e71367
Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well‐being. However, there are growing concerns about side‐effects related to sleep, cognition and new, or worsening mental health in a subset. This study assessed healthcare providers' perceptions of the positive and negative impacts of ETI and compared provider ratings in Europe to the United States. Methods: The European CF Society's Mental Health Working Group adapted and distributed the survey developed by the CF Foundation's Mental Health Advisory Committee. It assessed healthcare providers' observations of the impacts of ETI in these domains: (1) positive and negative physical and psychological effects, (2) sleep difficulties, (3) cognitive difficulties, (4) worsening mental health, and (5) concerns about the future and finances. Results: Seventy‐eight healthcare providers across 21 European (EU) countries responded, endorsing similar percentages of positive physical and psychological effects as US providers. However, in Europe lower percentages of MH side‐effects (e.g., increased depression/anxiety, suicidal ideation, body image), and concerns about the future (e.g., copays, food insecurity) were found. Conclusions: Across international providers similar positive results were reported. A substantial proportion of PWCF across EU and United States experienced ETI side‐effects related to sleep, cognition, and new or worsening mental health. However, EU providers reported significantly fewer side‐effects related to mental health, negative body image, planning for the future and finances. MH side‐effects led to dosing changes in ETI and in the United States, they led to changes in MH medications. These international data document the importance of systematically assessing and managing these side‐effects.
- 12 November 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (11) , e71367
Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well‐being. However, there are growing concerns about side‐effects related to sleep, cognition and new, or worsening mental health in a subset. This study assessed healthcare providers' perceptions of the positive and negative impacts of ETI and compared provider ratings in Europe to the United States. Methods: The European CF Society's Mental Health Working Group adapted and distributed the survey developed by the CF Foundation's Mental Health Advisory Committee. It assessed healthcare providers' observations of the impacts of ETI in these domains: (1) positive and negative physical and psychological effects, (2) sleep difficulties, (3) cognitive difficulties, (4) worsening mental health, and (5) concerns about the future and finances. Results: Seventy‐eight healthcare providers across 21 European (EU) countries responded, endorsing similar percentages of positive physical and psychological effects as US providers. However, in Europe lower percentages of MH side‐effects (e.g., increased depression/anxiety, suicidal ideation, body image), and concerns about the future (e.g., copays, food insecurity) were found. Conclusions: Across international providers similar positive results were reported. A substantial proportion of PWCF across EU and United States experienced ETI side‐effects related to sleep, cognition, and new or worsening mental health. However, EU providers reported significantly fewer side‐effects related to mental health, negative body image, planning for the future and finances. MH side‐effects led to dosing changes in ETI and in the United States, they led to changes in MH medications. These international data document the importance of systematically assessing and managing these side‐effects.
- Open Access
- 1 October 2025
- Published by Wiley
Advancing Mental Healthcare for Individuals with Cystic Fibrosis in Low- and Middle-Income Countries
Cystic fibrosis (CF) presents significant challenges for both patients and their families. However, the mental health needs of persons with cystic fibrosis (PWCF) in low- and middle-income countries (LMICs) remain underexplored. Limited resources, fragmented healthcare systems, and inequities in access to essential CF treatments often compound psychological stressors such as depression, anxiety, and caregiver burden. This review examines existing literature on the mental health and psychosocial challenges of PWCF and their families in LMICs, highlighting the intersection between inadequate physical healthcare and poor mental health outcomes. Findings suggest that disparities in access to diagnostic services, medications, and multidisciplinary care exacerbate emotional distress, leading to poorer quality of life compared to counterparts in high-income countries. Families often experience financial strain, social isolation, and limited psychosocial support, which further magnify mental health challenges. Addressing these inequities requires integrating mental health care into routine CF management, even in resource-limited settings. Low-cost strategies such as regular mental health screening, translating available CF-specific mental health resources, and the provision of brief interventions via digital and internet-based technologies show promise for sustainable implementation. The review underscores the need for increased research in LMIC contexts and the development of scalable interventions that address both physical and psychological dimensions of CF. Ensuring parity with high-income countries demands recognition of mental health as a core component of CF care.
- 1 October 2025
- Published by Wiley
Open AccessAdvancing Mental Healthcare for Individuals with Cystic Fibrosis in Low- and Middle-Income Countries
Cystic fibrosis (CF) presents significant challenges for both patients and their families. However, the mental health needs of persons with cystic fibrosis (PWCF) in low- and middle-income countries (LMICs) remain underexplored. Limited resources, fragmented healthcare systems, and inequities in access to essential CF treatments often compound psychological stressors such as depression, anxiety, and caregiver burden. This review examines existing literature on the mental health and psychosocial challenges of PWCF and their families in LMICs, highlighting the intersection between inadequate physical healthcare and poor mental health outcomes. Findings suggest that disparities in access to diagnostic services, medications, and multidisciplinary care exacerbate emotional distress, leading to poorer quality of life compared to counterparts in high-income countries. Families often experience financial strain, social isolation, and limited psychosocial support, which further magnify mental health challenges. Addressing these inequities requires integrating mental health care into routine CF management, even in resource-limited settings. Low-cost strategies such as regular mental health screening, translating available CF-specific mental health resources, and the provision of brief interventions via digital and internet-based technologies show promise for sustainable implementation. The review underscores the need for increased research in LMIC contexts and the development of scalable interventions that address both physical and psychological dimensions of CF. Ensuring parity with high-income countries demands recognition of mental health as a core component of CF care.
- Open Access
- 26 August 2025
- Published by Wiley
Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparison of Cystic Fibrosis Healthcare Providers’ Observations in Europe and the United States
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well-being. However, there are growing concerns about side-effects related to sleep, cognition and new or worsening mental health in a subset. This study assessed healthcare providers’ perceptions of the positive and negative impacts of ETI and compared provider ratings in Europe to the United States (US). Methods: The European CF Society’s Mental Health Working Group adapted and distributed the survey developed by the CF Foundation’s Mental Health Advisory Committee. It assessed healthcare providers’ observations of the impacts of ETI in these domains: 1) positive and negative physical and psychological effects, 2) sleep difficulties, 3) cognitive difficulties, 4) worsening mental health, and 5) concerns about the future and finances. Results: Seventy-eight healthcare providers across 21 European (EU) countries responded, endorsing similar percentages of positive physical and psychological effects as US providers. However, in Europe lower percentages of MH side-effects (e.g., increased depression/anxiety, suicidal ideation, body image), and concerns about the future (e.g., copays, food insecurity). Conclusions: Across international providers similar positive results were reported. A substantial proportion of PWCF across EU and US experienced ETI side-effects related to sleep, cognition, and new or worsening mental health. However, EU providers reported significantly fewer side-effects related to mental health, negative body image, planning for the future and finances. MH side-effects led to dosing changes in ETI and in the US, they led to changes in MH medications. These international data document the importance of systematically assessing and managing these side-effects.
- 26 August 2025
- Published by Wiley
Open AccessImpacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparison of Cystic Fibrosis Healthcare Providers’ Observations in Europe and the United States
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well-being. However, there are growing concerns about side-effects related to sleep, cognition and new or worsening mental health in a subset. This study assessed healthcare providers’ perceptions of the positive and negative impacts of ETI and compared provider ratings in Europe to the United States (US). Methods: The European CF Society’s Mental Health Working Group adapted and distributed the survey developed by the CF Foundation’s Mental Health Advisory Committee. It assessed healthcare providers’ observations of the impacts of ETI in these domains: 1) positive and negative physical and psychological effects, 2) sleep difficulties, 3) cognitive difficulties, 4) worsening mental health, and 5) concerns about the future and finances. Results: Seventy-eight healthcare providers across 21 European (EU) countries responded, endorsing similar percentages of positive physical and psychological effects as US providers. However, in Europe lower percentages of MH side-effects (e.g., increased depression/anxiety, suicidal ideation, body image), and concerns about the future (e.g., copays, food insecurity). Conclusions: Across international providers similar positive results were reported. A substantial proportion of PWCF across EU and US experienced ETI side-effects related to sleep, cognition, and new or worsening mental health. However, EU providers reported significantly fewer side-effects related to mental health, negative body image, planning for the future and finances. MH side-effects led to dosing changes in ETI and in the US, they led to changes in MH medications. These international data document the importance of systematically assessing and managing these side-effects.
- 2 June 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (9) , 2469-2477
Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with unprecedented clinical improvements, transforming the management of cystic fibrosis (CF). However, side effects with implications for safety and well‐being have been reported, including neuropsychiatric changes. This study aimed to better characterize the emerging positive and negative impacts of ETI.Methods: The Cystic Fibrosis Foundation's Mental Health Advisory Committee distributed a 26‐item survey to US CF care teams to assess clinician observations of patient‐reported experiences with ETI. Survey responses measured the prevalence of these effects in five domains: (1) positive physical and psychological effects, (2) sleep difficulties, (3) cognitive difficulties, (4) worsening mental health, and (5) concerns about the future and finances.Results: Seventy‐five healthcare providers responded from a pediatric, adult, and combined centers. Positive physical effects of ETI and increased optimism were reported in the upper quartiles (50%–100%) and rated as having a significant impact on daily functioning. Sleep and cognitive difficulties were reported in 1%–24%, with slight impacts on functioning, and psychological symptoms (e.g., increased stress, depression, anxiety) and new psychiatric medications were reported in 1%–24%, with moderate impacts. Concerns about the future were reported in 1%–24%, with minimal impacts.Conclusion: Across US centers, providers most often observed positive physical effects of ETI. However, a variety of negative side effects were also reported, including sleep disruptions and worsening psychological functioning, which should be systematically monitored by CF teams. These national‐level data are a first step in evaluating the prevalence and consequences of these side effects and can directly inform future studies.
- 2 June 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (9) , 2469-2477
Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with unprecedented clinical improvements, transforming the management of cystic fibrosis (CF). However, side effects with implications for safety and well‐being have been reported, including neuropsychiatric changes. This study aimed to better characterize the emerging positive and negative impacts of ETI.Methods: The Cystic Fibrosis Foundation's Mental Health Advisory Committee distributed a 26‐item survey to US CF care teams to assess clinician observations of patient‐reported experiences with ETI. Survey responses measured the prevalence of these effects in five domains: (1) positive physical and psychological effects, (2) sleep difficulties, (3) cognitive difficulties, (4) worsening mental health, and (5) concerns about the future and finances.Results: Seventy‐five healthcare providers responded from a pediatric, adult, and combined centers. Positive physical effects of ETI and increased optimism were reported in the upper quartiles (50%–100%) and rated as having a significant impact on daily functioning. Sleep and cognitive difficulties were reported in 1%–24%, with slight impacts on functioning, and psychological symptoms (e.g., increased stress, depression, anxiety) and new psychiatric medications were reported in 1%–24%, with moderate impacts. Concerns about the future were reported in 1%–24%, with minimal impacts.Conclusion: Across US centers, providers most often observed positive physical effects of ETI. However, a variety of negative side effects were also reported, including sleep disruptions and worsening psychological functioning, which should be systematically monitored by CF teams. These national‐level data are a first step in evaluating the prevalence and consequences of these side effects and can directly inform future studies.
- 4 April 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (6) , 1768-1776
National integration of mental health screening and treatment into specialized care for cystic fibrosis: What predicts success?
Objectives: The CF Foundation sponsored competitive awards for Mental Health Coordinators (MHCs) from 2016 to 2018 to implement the international guidelines for mental health screening and treatment in US CF centers. Longitudinal surveys evaluated success in implementing these guidelines using the Consolidated Framework for Implementation Research (CFIR).Methods: MHCs completed annual surveys assessing implementation from preparation/basic implementation (e.g., using recommended screeners) to full implementation/sustainability (e.g., providing evidence‐based treatments). Points were assigned to questions through consensus, with higher scores assigned to more complex tasks. Linear regression and mixed effects models were used to: (1) examine differences in centers and MHC characteristics, (2) identify predictors of success, (3) model the longitudinal trajectory of implementation scores.Results: A total of 122 MHCs (88.4% responded): Cohort 1,N = 80; Cohort 2,N = 30; and Cohort 3,N = 12. No differences in center characteristics were found. Significant improvements in implementation were observed across centers over time. Years of experience on a CF team was the only significant predictor of success; those with 1–5 years or longer reported the highest implementation scores. Change over time was predicted by >5 years of experience.Conclusions: Implementation of the mental health guidelines was highly successful over time. Funding for MHCs with dedicated time was critical. Longitudinal modeling indicated that CF centers with diverse characteristics could implement them, supported by evidence from the CF Patient Registry showing nearly universal uptake of mental health screening in the United States. Years of experience predicted better implementation, suggesting that education and training of MHCs and retention of experienced providers are critical to success.
- 4 April 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (6) , 1768-1776
National integration of mental health screening and treatment into specialized care for cystic fibrosis: What predicts success?
Objectives: The CF Foundation sponsored competitive awards for Mental Health Coordinators (MHCs) from 2016 to 2018 to implement the international guidelines for mental health screening and treatment in US CF centers. Longitudinal surveys evaluated success in implementing these guidelines using the Consolidated Framework for Implementation Research (CFIR).Methods: MHCs completed annual surveys assessing implementation from preparation/basic implementation (e.g., using recommended screeners) to full implementation/sustainability (e.g., providing evidence‐based treatments). Points were assigned to questions through consensus, with higher scores assigned to more complex tasks. Linear regression and mixed effects models were used to: (1) examine differences in centers and MHC characteristics, (2) identify predictors of success, (3) model the longitudinal trajectory of implementation scores.Results: A total of 122 MHCs (88.4% responded): Cohort 1,N = 80; Cohort 2,N = 30; and Cohort 3,N = 12. No differences in center characteristics were found. Significant improvements in implementation were observed across centers over time. Years of experience on a CF team was the only significant predictor of success; those with 1–5 years or longer reported the highest implementation scores. Change over time was predicted by >5 years of experience.Conclusions: Implementation of the mental health guidelines was highly successful over time. Funding for MHCs with dedicated time was critical. Longitudinal modeling indicated that CF centers with diverse characteristics could implement them, supported by evidence from the CF Patient Registry showing nearly universal uptake of mental health screening in the United States. Years of experience predicted better implementation, suggesting that education and training of MHCs and retention of experienced providers are critical to success.
- 23 December 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 207, 107095
Comparison of mental health in individuals with primary ciliary dyskinesia, cystic fibrosis, and parent caregivers
- 23 December 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 207, 107095
Comparison of mental health in individuals with primary ciliary dyskinesia, cystic fibrosis, and parent caregivers
- Open Access
- 16 December 2022
- Published by Wiley
National integration of mental health screening and treatment into specialized care for cystic fibrosis: What predicts success?
Objectives: The CF Foundation sponsored competitive awards for Mental Health Coordinators (MHCs) from 2016-2018 to implement the international guidelines for mental health screening and treatment in US CF centers. Longitudinal surveys evaluated success in implementing these guidelines using the Consolidated Framework for Implementation Research (CFIR). Methods: MHCs completed annual surveys assessing implementation from Preparation/Basic Implementation (e.g., using recommended screeners) to Full Implementation/Sustainability (e.g., providing evidence-based treatments). Points were assigned to questions through consensus, with higher scores assigned to more complex tasks. Linear regression and mixed effects models were used to: 1) examine differences in centers and MHC characteristics, 2) identify predictors of success, 3) model the longitudinal trajectory of implementation scores. Results: 122 MHCs (88.4% responded): Cohort 1 N =80, Cohort 2 N=30, Cohort 3 N =12. No differences in center characteristics were found. Significant improvements in implementation were observed across centers over time. Years of experience on a CF team was the only significant predictor of success; those with 1-5 years or longer reported the highest implementation scores. Change over time was predicted by >5 years of experience. Conclusions: Implementation of the mental health guidelines was highly successful over time. Funding for MHCs with dedicated time was critical. Longitudinal modeling indicated that CF centers with diverse characteristics could implement them, supported by evidence from the CF Patient Registry showing nearly universal uptake of mental health screening in the US. Years of experience predicted better implementation, suggesting that education and training of MHCs and retention of experienced providers are critical to success.
- 16 December 2022
- Published by Wiley
Open AccessNational integration of mental health screening and treatment into specialized care for cystic fibrosis: What predicts success?
Objectives: The CF Foundation sponsored competitive awards for Mental Health Coordinators (MHCs) from 2016-2018 to implement the international guidelines for mental health screening and treatment in US CF centers. Longitudinal surveys evaluated success in implementing these guidelines using the Consolidated Framework for Implementation Research (CFIR). Methods: MHCs completed annual surveys assessing implementation from Preparation/Basic Implementation (e.g., using recommended screeners) to Full Implementation/Sustainability (e.g., providing evidence-based treatments). Points were assigned to questions through consensus, with higher scores assigned to more complex tasks. Linear regression and mixed effects models were used to: 1) examine differences in centers and MHC characteristics, 2) identify predictors of success, 3) model the longitudinal trajectory of implementation scores. Results: 122 MHCs (88.4% responded): Cohort 1 N =80, Cohort 2 N=30, Cohort 3 N =12. No differences in center characteristics were found. Significant improvements in implementation were observed across centers over time. Years of experience on a CF team was the only significant predictor of success; those with 1-5 years or longer reported the highest implementation scores. Change over time was predicted by >5 years of experience. Conclusions: Implementation of the mental health guidelines was highly successful over time. Funding for MHCs with dedicated time was critical. Longitudinal modeling indicated that CF centers with diverse characteristics could implement them, supported by evidence from the CF Patient Registry showing nearly universal uptake of mental health screening in the US. Years of experience predicted better implementation, suggesting that education and training of MHCs and retention of experienced providers are critical to success.